AU2015335992A1 - Nargenicin compounds and uses thereof as antibacterial agents - Google Patents

Nargenicin compounds and uses thereof as antibacterial agents Download PDF

Info

Publication number
AU2015335992A1
AU2015335992A1 AU2015335992A AU2015335992A AU2015335992A1 AU 2015335992 A1 AU2015335992 A1 AU 2015335992A1 AU 2015335992 A AU2015335992 A AU 2015335992A AU 2015335992 A AU2015335992 A AU 2015335992A AU 2015335992 A1 AU2015335992 A1 AU 2015335992A1
Authority
AU
Australia
Prior art keywords
6alkyl
arya
ring
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015335992A
Other languages
English (en)
Inventor
James M. Apgar
Qun Dang
Mihir Mandal
Dongfang Meng
David B. Olsen
Ronald E. Painter
Dann Parker
Sheo B. Singh
Jing Su
Takao Suzuki
Robert R. Wilkening
Lihu Yang
Katherine Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2015335992A1 publication Critical patent/AU2015335992A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/06Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16Halogenated acetic acids
    • C07C53/18Halogenated acetic acids containing fluorine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2015335992A 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents Abandoned AU2015335992A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2014/089204 WO2016061772A1 (en) 2014-10-22 2014-10-22 Nargenicin compounds and uses thereof as antibacterial agents
AUPCT/CN2014/089204 2014-10-22
PCT/US2015/056627 WO2016064982A1 (en) 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents

Publications (1)

Publication Number Publication Date
AU2015335992A1 true AU2015335992A1 (en) 2017-04-20

Family

ID=55760063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015335992A Abandoned AU2015335992A1 (en) 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents

Country Status (11)

Country Link
US (2) US9944654B2 (https=)
EP (1) EP3209667B1 (https=)
JP (1) JP2017533200A (https=)
KR (1) KR20170070197A (https=)
CN (1) CN107108646A (https=)
AU (1) AU2015335992A1 (https=)
BR (1) BR112017008101A2 (https=)
CA (1) CA2964377A1 (https=)
MX (1) MX2017005271A (https=)
RU (1) RU2017117253A (https=)
WO (2) WO2016061772A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
KR102440647B1 (ko) 2020-07-28 2022-09-06 선문대학교 산학협력단 나르제니신 a1 유도체를 포함하는 항혈관신생용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148883A (en) 1977-08-18 1979-04-10 Pfizer Inc. Antibiotics produced by new species of nocardia
US4360683A (en) * 1980-08-06 1982-11-23 The Upjohn Company Antibiotic nodusmicin derivatives
US4351769A (en) * 1980-08-25 1982-09-28 The Upjohn Company Antibiotic composition of matter
US4448970A (en) * 1981-02-19 1984-05-15 The Upjohn Company Nargenicin derivatives
US4436747A (en) 1982-10-21 1984-03-13 Pfizer Inc. Nargenicin C1
US4605624A (en) * 1982-10-21 1986-08-12 Pfizer Inc. Nocardia species capable of producing nargenicin C1
ES2258234T3 (es) 2002-08-12 2006-08-16 PHARMACIA & UPJOHN COMPANY LLC N-aril-2-oxazolidinonas y sus derivados.
GB0227701D0 (en) 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
MXPA05005522A (es) 2002-11-28 2005-07-25 Astrazeneca Ab Oxazolidinonas como agentes antibacterianos.
WO2005012270A2 (en) 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
JP2008500318A (ja) 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 抗菌剤としての3−{4−(ピリジン−3−イル)フェニル}−5−(1h−1,2,3−トリアゾール−1−イルメチル)−1,3−オキサゾリジン−2−オン
WO2007133803A2 (en) 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
WO2008069619A1 (en) 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
KR101040468B1 (ko) 2008-02-29 2011-06-09 조선대학교산학협력단 새로운 노카르디아 속 균주 및 그의 발효 배양물의 용도
KR101022564B1 (ko) 2008-12-19 2011-03-16 조선대학교산학협력단 나르제니신을 포함하는 염증성 신경퇴행성 질환의 치료용 제약 조성물
WO2011139832A2 (en) 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents

Also Published As

Publication number Publication date
CN107108646A (zh) 2017-08-29
KR20170070197A (ko) 2017-06-21
EP3209667A1 (en) 2017-08-30
CA2964377A1 (en) 2016-04-28
RU2017117253A (ru) 2018-11-23
EP3209667A4 (en) 2018-06-06
JP2017533200A (ja) 2017-11-09
RU2017117253A3 (https=) 2019-04-16
US10144741B2 (en) 2018-12-04
WO2016064982A1 (en) 2016-04-28
EP3209667B1 (en) 2025-03-19
US9944654B2 (en) 2018-04-17
WO2016061772A1 (en) 2016-04-28
MX2017005271A (es) 2017-08-15
US20180186808A1 (en) 2018-07-05
BR112017008101A2 (pt) 2018-02-20
US20170305924A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CN108135887B (zh) 噁唑烷酮化合物及其作为抗菌剂的使用方法
CN110003253A (zh) 三环苯并氧杂硼杂环戊烯化合物及其用途
KR20160141770A (ko) 항균 화합물
US10144741B2 (en) Nargenicin compounds and uses thereof as antibacterial agents
US12365656B2 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
US10752621B2 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
CA3145555C (en) Compounds and methods of use thereof as antibacterial agents
DK2897970T3 (en) MACROLIDE DERIVATIVES, PREPARING thereof, AND THERAPEUTIC APPLICATION
CN111527093B (zh) 抗菌杂环化合物及其合成
RU2794494C2 (ru) Оксазолидиноновые соединения и способы их применения в качестве противобактериальных средств
CN109121397A (zh) 杂环化合物,特别是2-氧代-4,4,5,5,6,6,7,7-八氢苯并噁唑衍生物以及它们作为抗菌化合物的用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted